Will take responsibility for the clinical development of pipeline of gene and cell therapies
Oxford BioMedica, a UK developer of gene-based medicines and therapeutic vaccines, has appointed Dr Paul Blake to the Executive Management team as Chief Development Officer, with effect from 1 September 2014. Blake, previously a Non-Executive Director of the company, will remain a member of the Board and take responsibility for the clinical development of Oxford BioMedica’s pipeline of gene and cell therapies.
Blake joined the Board of Oxford BioMedica in January 2010. He is a senior pharmaceutical executive with more than 30 years’ experience gained from roles in international pharmaceutical and biotech companies and he has been involved in the development of many drugs and vaccines including Parkinson's Disease treatment Requip, heart treatment Coreg and sleepiness drug Provigil.
Most recently, Blake was Senior Vice President and Chief Medical Officer of Æterna Zentaris.